{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:01:34Z","timestamp":1791270094134,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1093\/brain\/awu409","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T03:03:39Z","timestamp":1423623819000},"page":"963-973","source":"Crossref","is-referenced-by-count":148,"title":["Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study"],"prefix":"10.1093","volume":"138","author":[{"given":"Per","family":"Svenningsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Rosenblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"af Edholm Arvidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Wictorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Keywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bavani","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Widner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,5]]},"reference":[{"key":"key\n\t\t\t\t20170425185111_awu409-B1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B4","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170425185111_awu409-B5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"key\n\t\t\t\t20170425185111_awu409-B8","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"key\n\t\t\t\t20170425185111_awu409-B9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/187152711797247885","article-title":"Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease","volume":"10","author":"Cenci","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"key\n\t\t\t\t20170425185111_awu409-B10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","article-title":"Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"11","author":"da Silva-J\u00fanior","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mds.1112","article-title":"Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study","volume":"16","author":"Del Dotto","year":"2001","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B7","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"key":"key\n\t\t\t\t20170425185111_awu409-B11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004850-199409000-00007","article-title":"Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo- and baseline-controlled multi-centre study. The Eltoprazine Aggression Research Group","volume":"9","author":"de Koning","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170425185111_awu409-B12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mds.870090403","article-title":"Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment","volume":"9","author":"Goetz","year":"1994","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","article-title":"N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease","volume":"48","author":"Greenamyre","year":"1991","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20170425185111_awu409-B16","first-page":"534","article-title":"Abnormal involuntary movement scale","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"key\n\t\t\t\t20170425185111_awu409-B17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0","article-title":"Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale","volume":"14","author":"Hagell","year":"1999","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-3565(25)31520-X","article-title":"Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity","volume":"208","author":"Hollister","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20170425185111_awu409-B19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t20170425185111_awu409-B20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","article-title":"Buspirone in the treatment of levodopa induced dyskinesias","volume":"54","author":"Kleedorfer","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20170425185111_awu409-B21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/0140-6736(93)90385-T","article-title":"Eltoprazine for aggression in mental handicap","volume":"341","author":"Kohen","year":"1993","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170425185111_awu409-B22","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson\u2019s Disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170425185111_awu409-B23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.170.3953.76","article-title":"L-Dopainduced release of cerebral monoamines","volume":"170","author":"Ng","year":"1970","journal-title":"Science"},{"key":"key\n\t\t\t\t20170425185111_awu409-B25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/230331a0","article-title":"Effects of L-dopa on efflux of cerebral monoamines from synaptosomes","volume":"230","author":"Ng","year":"1971","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170425185111_awu409-B26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci"},{"key":"key\n\t\t\t\t20170425185111_awu409-B27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170425185111_awu409-B28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2125.1990.tb05454.x","article-title":"Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration","volume":"30","author":"Raghoebar","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170425185111_awu409-B29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/jnnp.2003.022780","article-title":"Use and interpretation of on\/off diaries in parkinson\u2019s disease","volume":"75","author":"Reimer","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20170425185111_awu409-B30","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine study group. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170425185111_awu409-B31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"key\n\t\t\t\t20170425185111_awu409-B32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0140-6736(93)92660-L","article-title":"Eltoprazine for aggression in schizophrenia and mental retardation","volume":"341","author":"Tiihonen","year":"1993","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170425185111_awu409-B33","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20170425185111_awu409-B34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0140-6736(92)93050-W","article-title":"Eltoprazine in mentally retarded self-injuring patients","volume":"340","author":"Verhoeven","year":"1992","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170425185111_awu409-B35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1517\/17425255.2011.580275","article-title":"Pharmacokinetic evaluation of eltoprazine","volume":"7","author":"Wigal","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t20170425185111_awu409-B36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/138\/4\/963\/13798742\/awu409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T20:34:30Z","timestamp":1747600470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awu409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,5]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,2,5]]},"published-print":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awu409","relation":{},"ISSN":["1460-2156","0006-8950"],"issn-type":[{"value":"1460-2156","type":"electronic"},{"value":"0006-8950","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,5]]}}}